Eyepoint Pharmaceuticals Inc (EYPT)

$17.08 -0.74 (-4.15%)
Market Cap 1.47B
Revenue (ttm) 43.27M
Net Income (ttm) -130.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -302.45%
Debt to Equity Ratio 0.00
Volume 1,429,818
Avg Vol 1,347,702
Day's Range N/A - N/A
Shares Out 82.79M
Stochastic %K 98%
Beta 1.67
Analysts Strong Sell
Price Target $34.00

Company Profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clin...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 926 5000
Fax: 617 926 5050
Address:
480 Pleasant Street, Suite C-400, Watertown, United States
rizzato
rizzato Jan. 9 at 9:30 PM
$EYPT a good question today could be who is selling ? Any idea?
0 · Reply
rizzato
rizzato Jan. 9 at 6:12 PM
$EYPT After the news we went up till 18.20 and back again . Good job guys please let me know when you will stop adding more and I can be back to look the share price because -4% with no volume is very boring
0 · Reply
rizzato
rizzato Jan. 9 at 3:49 PM
$EYPT good news and red share price , hahahahahahahaha, they are genius
0 · Reply
rizzato
rizzato Jan. 9 at 2:53 PM
$EYPT still adding more from them
0 · Reply
IsaacRowe
IsaacRowe Jan. 8 at 7:57 PM
$EYPT thin tape biotech, watch for quiet accumulation then volume ignition through the range top
2 · Reply
brucino
brucino Jan. 8 at 10:47 AM
$EYPT È vero i TP sono di solito a lungo termine, ma io vedo da mesi ,per non dire da anni obbiettivi di prezzo che vanno da 20 a 68 (!!) $. Ci arriverà mai a metà strada tra questi due prezzi???
1 · Reply
rizzato
rizzato Jan. 7 at 6:14 PM
$EYPT price as always totally controlled by institution if they are not interested to push it up probably because someone want to add more shares at lower price we do not have any chance to go up
1 · Reply
rizzato
rizzato Jan. 7 at 6:06 PM
$EYPT they probably need to buy more before to leave us to go up again
0 · Reply
rizzato
rizzato Jan. 7 at 5:05 PM
$EYPT still low volume
0 · Reply
Quantumup
Quantumup Jan. 7 at 3:31 PM
Mizuho reiterated $EYPT at Top Pick, Outperform and a $33 PT. $OCUL $FDMT REGN $SRZN $KOD Here's what Mizuho said in its note to investors: This morning, EYPT provided a corporate update outlining key milestones anticipated for 2026. Importantly, the company remains on track to report top-line P3 data in mid-2026 for lead asset Duravyu, a novel (and potentially disruptive) extended-duration treatment in the setting of wet AMD/wAMD. Additionally, EYPT also remains on track in dose the first patient in its P3 program for Duravyu in diabetic macular edema/DME in 1Q26. With the company also announcing today it has ~$300MN in cash and investments (unaudited) at YE25—with a solid cash runway into 4Q27—we find EYPT well-positioned to deliver on its key milestones in wAMD and DME in what we view to be a transformative year for the company. As such, we again highlight EYPT as a top pick for 2026.
1 · Reply
Latest News on EYPT
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

Jan 7, 2026, 7:00 AM EST - 4 days ago

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 7:00 AM EST - 25 days ago

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 16, 2025, 7:00 AM EST - 26 days ago

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Nov 19, 2025, 7:00 AM EST - 7 weeks ago

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 2:31 PM EST - 2 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2025 Earnings Call Transcript

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Nov 5, 2025, 7:00 AM EST - 2 months ago

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

EyePoint Announces Participation at Upcoming Investor Conferences

Nov 3, 2025, 7:00 AM EST - 2 months ago

EyePoint Announces Participation at Upcoming Investor Conferences

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 29, 2025, 7:00 AM EDT - 2 months ago

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study

Oct 15, 2025, 11:01 AM EDT - 3 months ago

EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study

EyePoint Announces Pricing of Public Offering

Oct 14, 2025, 10:43 PM EDT - 3 months ago

EyePoint Announces Pricing of Public Offering

EyePoint Announces Proposed Public Offering of Common Stock

Oct 14, 2025, 4:35 PM EDT - 3 months ago

EyePoint Announces Proposed Public Offering of Common Stock

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

Oct 14, 2025, 4:01 PM EDT - 3 months ago

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 6:03 PM EDT - 4 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School Conference Transcript

EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:09 PM EDT - 5 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call Transcript

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 7:30 AM EDT - 5 months ago

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Aug 6, 2025, 7:00 AM EDT - 5 months ago

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 30, 2025, 7:00 AM EDT - 5 months ago

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Jul 29, 2025, 7:00 AM EDT - 5 months ago

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

Jun 12, 2025, 11:03 AM EDT - 7 months ago

EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

May 27, 2025, 7:00 AM EDT - 8 months ago

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 16, 2025, 7:00 AM EDT - 8 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript

May 7, 2025, 2:49 PM EDT - 8 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

May 7, 2025, 7:00 AM EDT - 8 months ago

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 30, 2025, 7:00 AM EDT - 9 months ago

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 27, 2025, 7:00 AM EDT - 10 months ago

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 2:51 PM EST - 11 months ago

EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

Mar 5, 2025, 7:00 AM EST - 11 months ago

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

Feb 26, 2025, 7:00 AM EST - 11 months ago

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 11 months ago

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival

Jan 30, 2025, 12:39 PM EST - 1 year ago

EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

Jan 8, 2025, 7:00 AM EST - 1 year ago

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

Dec 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

Nov 14, 2024, 5:04 AM EST - 1 year ago

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Nov 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Oct 31, 2024, 4:00 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

Oct 29, 2024, 9:47 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 5:14 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

Oct 28, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

Oct 24, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

Sep 4, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 29, 2024, 5:35 PM EDT - 1 year ago

EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 8, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

Jun 18, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

May 8, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program

May 7, 2024, 12:50 PM EDT - 1 year ago

EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program

EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goal

May 6, 2024, 9:10 AM EDT - 1 year ago

EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goal

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

May 6, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

Apr 2, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

rizzato
rizzato Jan. 9 at 9:30 PM
$EYPT a good question today could be who is selling ? Any idea?
0 · Reply
rizzato
rizzato Jan. 9 at 6:12 PM
$EYPT After the news we went up till 18.20 and back again . Good job guys please let me know when you will stop adding more and I can be back to look the share price because -4% with no volume is very boring
0 · Reply
rizzato
rizzato Jan. 9 at 3:49 PM
$EYPT good news and red share price , hahahahahahahaha, they are genius
0 · Reply
rizzato
rizzato Jan. 9 at 2:53 PM
$EYPT still adding more from them
0 · Reply
IsaacRowe
IsaacRowe Jan. 8 at 7:57 PM
$EYPT thin tape biotech, watch for quiet accumulation then volume ignition through the range top
2 · Reply
brucino
brucino Jan. 8 at 10:47 AM
$EYPT È vero i TP sono di solito a lungo termine, ma io vedo da mesi ,per non dire da anni obbiettivi di prezzo che vanno da 20 a 68 (!!) $. Ci arriverà mai a metà strada tra questi due prezzi???
1 · Reply
rizzato
rizzato Jan. 7 at 6:14 PM
$EYPT price as always totally controlled by institution if they are not interested to push it up probably because someone want to add more shares at lower price we do not have any chance to go up
1 · Reply
rizzato
rizzato Jan. 7 at 6:06 PM
$EYPT they probably need to buy more before to leave us to go up again
0 · Reply
rizzato
rizzato Jan. 7 at 5:05 PM
$EYPT still low volume
0 · Reply
Quantumup
Quantumup Jan. 7 at 3:31 PM
Mizuho reiterated $EYPT at Top Pick, Outperform and a $33 PT. $OCUL $FDMT REGN $SRZN $KOD Here's what Mizuho said in its note to investors: This morning, EYPT provided a corporate update outlining key milestones anticipated for 2026. Importantly, the company remains on track to report top-line P3 data in mid-2026 for lead asset Duravyu, a novel (and potentially disruptive) extended-duration treatment in the setting of wet AMD/wAMD. Additionally, EYPT also remains on track in dose the first patient in its P3 program for Duravyu in diabetic macular edema/DME in 1Q26. With the company also announcing today it has ~$300MN in cash and investments (unaudited) at YE25—with a solid cash runway into 4Q27—we find EYPT well-positioned to deliver on its key milestones in wAMD and DME in what we view to be a transformative year for the company. As such, we again highlight EYPT as a top pick for 2026.
1 · Reply
Reanimated666
Reanimated666 Jan. 7 at 2:37 PM
$EYPT
0 · Reply
brucino
brucino Jan. 7 at 1:54 PM
$EYPT Nonostante la news( che non è la news dell' anno)..piattaforma anche oggi.
1 · Reply
Reanimated666
Reanimated666 Jan. 7 at 1:22 PM
$EYPT Gap 🆙
0 · Reply
Manalishi
Manalishi Jan. 7 at 12:38 PM
$EYPT https://investors.eyepoint.bio/node/19641/pdf
1 · Reply
rizzato
rizzato Jan. 6 at 6:16 PM
$EYPT The situation is still the same, institutional are fully in and still own the main shares numbers Work in progress of the company is fine Market is without limit So why we are dropping?
1 · Reply
Harpua_dumphuk
Harpua_dumphuk Jan. 6 at 4:30 PM
$EYPT We started the New Year with some profit taking after that big rally. It looks good, dropping to support and then a pop after that. The sector dropped so this isn't an EYPT thing. Here is the 15-minute chart showing the basing out. Now that idiot running the country needs to stop the BS otherwise this market will drop hard.
4 · Reply
rizzato
rizzato Jan. 6 at 4:11 PM
$EYPT EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference DEC 17, 2025 PDF Version WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 a.m. PT/10:30 a.m. ET. A webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepoint.bio. coming soon , and hopefully will gave us more investor and price up
0 · Reply
rizzato
rizzato Jan. 6 at 1:00 PM
$EYPT EyePoint, Inc. Common Stock (EYPT) Short Interest still dxatet December 15th but soon the December 31 th just to have an idea of the situation
0 · Reply
Reanimated666
Reanimated666 Jan. 5 at 8:56 PM
$EYPT Beautiful 🤩 close
1 · Reply
Reanimated666
Reanimated666 Jan. 5 at 4:32 PM
$EYPT My father was greatly knowledgeable and respected in the optometrist field. Had one of the top 50 biggest practices in the US. Have owned privately for years before it was public. I see the stock doubling in price with a 35 to 40 buck price objective
0 · Reply
rizzato
rizzato Jan. 5 at 1:37 PM
$EYPT here we are , from today everyone is back from the Christmas holiday . what should we see todays and in the coming days? should we find again the green highway to the top? let's see
1 · Reply
rizzato
rizzato Jan. 3 at 11:30 PM
$EYPT venezuela situation will help us, not or what will be happen Monday?
0 · Reply